Phase I/II proof-of-concept trial of calcipotriol, formulated with AKVANO, for the topical treatment of patients with psoriasis vulgaris.

Trial Profile

Phase I/II proof-of-concept trial of calcipotriol, formulated with AKVANO, for the topical treatment of patients with psoriasis vulgaris.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 30 Aug 2013

At a glance

  • Drugs Calcipotriol (Primary)
  • Indications Psoriasis
  • Focus Therapeutic Use
  • Most Recent Events

    • 30 Aug 2013 New trial record
    • 27 Aug 2013 Results have been reported in a Karolinska Development AB media release. Infiltrate thickness reduction was achieved and the drug was well tolerated.
    • 27 Aug 2013 Primary endpoint 'Clinical-response-rate' (infiltrate thickness reduction) has been met according to a Karolinska Development AB media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top